653 related articles for article (PubMed ID: 32635934)
1. TREM2 ectodomain and its soluble form in Alzheimer's disease.
Yang J; Fu Z; Zhang X; Xiong M; Meng L; Zhang Z
J Neuroinflammation; 2020 Jul; 17(1):204. PubMed ID: 32635934
[TBL] [Abstract][Full Text] [Related]
2. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
[TBL] [Abstract][Full Text] [Related]
3. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
[TBL] [Abstract][Full Text] [Related]
5. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.
Suárez-Calvet M; Kleinberger G; Araque Caballero MÁ; Brendel M; Rominger A; Alcolea D; Fortea J; Lleó A; Blesa R; Gispert JD; Sánchez-Valle R; Antonell A; Rami L; Molinuevo JL; Brosseron F; Traschütz A; Heneka MT; Struyfs H; Engelborghs S; Sleegers K; Van Broeckhoven C; Zetterberg H; Nellgård B; Blennow K; Crispin A; Ewers M; Haass C
EMBO Mol Med; 2016 May; 8(5):466-76. PubMed ID: 26941262
[TBL] [Abstract][Full Text] [Related]
6. CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau.
Henjum K; Quist-Paulsen E; Zetterberg H; Blennow K; Nilsson LNG; Watne LO
J Neuroinflammation; 2018 Nov; 15(1):304. PubMed ID: 30390679
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.
Ma LZ; Tan L; Bi YL; Shen XN; Xu W; Ma YH; Li HQ; Dong Q; Yu JT
Mol Neurodegener; 2020 Apr; 15(1):25. PubMed ID: 32276587
[TBL] [Abstract][Full Text] [Related]
8. The
Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
[TBL] [Abstract][Full Text] [Related]
9. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.
Park SH; Lee EH; Kim HJ; Jo S; Lee S; Seo SW; Park HH; Koh SH; Lee JH
Sci Rep; 2021 Jun; 11(1):13050. PubMed ID: 34158530
[TBL] [Abstract][Full Text] [Related]
10. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.
Moutinho M; Coronel I; Tsai AP; Di Prisco GV; Pennington T; Atwood BK; Puntambekar SS; Smith DC; Martinez P; Han S; Lee Y; Lasagna-Reeves CA; Lamb BT; Bissel SJ; Nho K; Landreth GE
Genome Med; 2023 Feb; 15(1):11. PubMed ID: 36805764
[TBL] [Abstract][Full Text] [Related]
11. TREM2 expression in the brain and biological fluids in prion diseases.
Diaz-Lucena D; Kruse N; Thüne K; Schmitz M; Villar-Piqué A; da Cunha JEG; Hermann P; López-Pérez Ó; Andrés-Benito P; Ladogana A; Calero M; Vidal E; Riggert J; Pineau H; Sim V; Zetterberg H; Blennow K; Del Río JA; Marín-Moreno A; Espinosa JC; Torres JM; Sánchez-Valle R; Mollenhauer B; Ferrer I; Zerr I; Llorens F
Acta Neuropathol; 2021 Jun; 141(6):841-859. PubMed ID: 33881612
[TBL] [Abstract][Full Text] [Related]
12. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification.
Knapskog AB; Henjum K; Idland AV; Eldholm RS; Persson K; Saltvedt I; Watne LO; Engedal K; Nilsson LNG
Sci Rep; 2020 Sep; 10(1):15886. PubMed ID: 32985583
[TBL] [Abstract][Full Text] [Related]
15. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
[TBL] [Abstract][Full Text] [Related]
16. Soluble TREM2 ameliorates tau phosphorylation and cognitive deficits through activating transgelin-2 in Alzheimer's disease.
Zhang X; Tang L; Yang J; Meng L; Chen J; Zhou L; Wang J; Xiong M; Zhang Z
Nat Commun; 2023 Oct; 14(1):6670. PubMed ID: 37865646
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
[TBL] [Abstract][Full Text] [Related]
18. Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer's disease.
Wang L; Nykänen NP; Western D; Gorijala P; Timsina J; Li F; Wang Z; Ali M; Yang C; Liu M; Brock W; Marquié M; Boada M; Alvarez I; Aguilar M; Pastor P; Ruiz A; Puerta R; Orellana A; Rutledge J; Oh H; Greicius MD; Le Guen Y; Perrin RJ; Wyss-Coray T; Jefferson A; Hohman TJ; Graff-Radford N; Mori H; Goate A; Levin J; Sung YJ; Cruchaga C
Mol Neurodegener; 2024 Jan; 19(1):1. PubMed ID: 38172904
[TBL] [Abstract][Full Text] [Related]
19. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid.
Winfree RL; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Jefferson AL; Hohman TJ;
Neurobiol Aging; 2022 Oct; 118():88-98. PubMed ID: 35908327
[TBL] [Abstract][Full Text] [Related]
20. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
Zhong L; Xu Y; Zhuo R; Wang T; Wang K; Huang R; Wang D; Gao Y; Zhu Y; Sheng X; Chen K; Wang N; Zhu L; Can D; Marten Y; Shinohara M; Liu CC; Du D; Sun H; Wen L; Xu H; Bu G; Chen XF
Nat Commun; 2019 Mar; 10(1):1365. PubMed ID: 30911003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
